Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer

Abstract

For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

“… 1 In contrast to small cell lung cancer, non–small cell lung cancer (NSCLC) accounts for more than 80% of cases of lung cancer, 2 and multimodal treatment, including surgery, radiotherapy, and systemic treatment, is the main therapeutic strategy based on the clinical stage of the tumors and the feasibility based on the underlying patient-related factors. 3 , 4 …”

“…1 In contrast to small cell lung cancer, non-small cell lung cancer (NSCLC) accounts for more than 80% of cases of lung cancer, 2 and multimodal treatment, including surgery, radiotherapy, and systemic treatment, is the main therapeutic strategy based on the clinical stage of the tumors and the feasibility based on the underlying patient-related factors. 3,4 Before the era of targeted therapy, platinumbased doublet chemotherapy was the standard Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations 2 journals.sagepub.com/home/tar…”

Azide-Locked Prodrug Co-Assembly into Nanoparticles with Indocyanine Green for Chemophotothermal Therapy

“…Then, the crude product was purified by column chromatography (V EA :V MeOH = 10:1) to obtain pure N 3 -GT-CPT as a yellowwhite solid (30.1 mg, 60.80%). 1 used against deionized water for 24 h to remove the DMSO solvent. Finally, a concentration of N 3 -GT-CPT/ICG NPs solution was adjusted to 1 mg/mL for further experiments.…”

“…Positive therapeutic effect in cancer relies heavily on drug delivery technology to surmount a series of biological barriers and precisely deliver drugs to the target site. Presently, therapeutic strategies such as chemotherapy, surgery, and immunotherapy play an important role in clinical treatment of tumors. − However, the low delivery efficiency and weak sensitivity to the tumor microenvironment (TME) limit the treatment outcomes. Thus, it is necessary to develop an advanced delivery technology to promote the development of tumor therapy. − Nanomedicine-based delivery technology can effectively improve drug distribution through selective response to TME. − To investigate this, various matrix materials such as liposomes, − inorganic nanoparticles, − polymeric prodrugs, − small molecular drugs, − and organic/inorganic hybrid matter − have been used for designing the drug carrier.…”

Nrf-2 as a novel target in radiation induced lung injury

“…Radiotherapy is one of the main treatments for malignant tumors, especially lung cancer. It can be potentially helpful in different types and stages of lung cancer, both in controlling cancer progression and palliative care [ 1 , 2 ]. With advances in treatment techniques and improvements in radiotherapy (RT), the adverse effects of RT have gradually decreased, and treatment outcomes have improved.…”